Core Insights - In 2024, a total of 100 new companies are expected to be listed on the A-share market, with an overall net profit increase of 1.18% compared to 2023, outperforming the existing listed companies which saw a decline of 5.44% [1][2][5] - Among the 100 new listings, 57 companies reported profit growth, while 43 experienced significant declines in their first year, with two companies seeing a drop of over 80% [1][5] - The recent regulatory change allows IPO companies to obtain a credit report in just half a day, significantly reducing the time and cost associated with the IPO process [1][19][20] Summary by Category Overall Performance - The 100 new companies collectively achieved a net profit of 18.9 billion yuan in 2024, marking a 1.18% increase from 2023 [1][3] - Excluding bank stocks, the overall A-share market saw a net profit decline of 5.44% [1][2] Sector Performance - Shanghai Main Board: New listings saw a net profit decline of 8.74%, while existing companies reported a 2.95% increase [2][3] - Shenzhen Main Board: New listings experienced a 46.54% profit increase, contrasting with a 25.89% decline for existing companies [2][4] - Sci-Tech Innovation Board: New listings had an 18.56% profit decline, while existing companies saw a 41.65% drop [2][4] - Growth Enterprise Market: New listings reported a 6.22% profit increase, while existing companies declined by 13.49% [2][4] - Beijing Stock Exchange: New listings had a 4.53% profit increase, while existing companies declined by 27.6% [2][4] Performance of New Listings - 57 out of 100 new companies reported profit growth, while 43 faced profit declines, with over 50% of the declines occurring in the Shenzhen Main Board and Sci-Tech Innovation Board [5][6] - The top 10 companies with the largest profit declines included 盛景微 (Shengjingwei) with a decline of 88.24% and 艾罗能源 (Ailuo Energy) with a decline of 80.88% [7][8] IPO Process Improvement - The new credit report system allows companies to replace the traditional requirement for a non-violation certificate, streamlining the IPO process and reducing the time from several months to a single day [19][20]

5月6日～5月11日当周，沪深北交易所新增受理2单上市申请，另有2家拟IPO企业终止审核，1家企业注 册生效。 5月6日～5月11日当周（下同），沪深北交易所新增受理2单上市申请，另有2家拟IPO企业终止审核，1 家企业注册生效。 上述2单上市申请均是在5月9日获得受理，一单为申报沪市科创板的宁波健信超导科技股份有限公司 （下称"健信超导"），这是今年上交所也是科创板第3家获得受理的企业；另一单是申报北交所的杭州 联川生物技术股份有限公司（下称"联川生物"），曾申报科创板IPO未果，转道北交所后融资规模缩水 一半。 至此，今年以来沪深北交易所共新增受理13单上市申请，其中上交所3单、深交所1单、北交所9单。 另有2家拟IPO企业终止审核，分别为申报沪市主板的无锡烨隆精密机械股份有限公司（下称"烨隆股 份"）、申报深市主板的深圳好博窗控技术股份有限公司（下称"好博窗控"）。其中，烨隆股份过会一 年多后撤单，该公司核心产品为涡轮壳产品，而纯电动汽车无须配备涡轮增压器，业务发展受新能源汽 车技术影响；好博窗控存在业绩增速放缓或业绩下滑风险。 当周，还有1家企业的IPO申请注册生效，即申报深市主板的悍高集团股份有限公 ...

文/梧桐晓编 5月9日，有2家IPO获得受理：宁波健信超导科技科创IPO、杭州联川生物技术（874281）北交所IPO。2家都是浙江公司。截至5月9日，沪深北3家交易所2025年共 受理12家IPO申报企业。健信超导2024年营收同比下降，扣非净利润同比增长至5027万元。报告期研发投入比5.86%，略超5%的标准。联川生物主要供应商 Illumina被列入不可靠清单，报告期内前五大客户均为大学及其附属机构。 一、宁波健信超导科技股份有限公司科创板IPO 公司前身宁波凯方核磁技术有限公司（港资独资）成立于2013年12月，2015年10月更名为宁波健信核磁技术有限公司，2022年11月整体变更并更名为宁波健信超 导科技股份公司。目前注册资本1.2576亿元。 （一）控股股东、实际控制人 公司控股股东为许建益先生，直接持有公司41.51%股份。公司实际控制人为许建益、许卉、许电波。三人合计控制公司59.92%表决权。其中，许建益系许卉、许 电波之父，许电波、许卉系兄妹关系。许建益出生于1953年，初中学历，现任公司董事长。许卉出生于1982年，研究生学历，现任公司董事、董事会秘书。许电 波出生于1978年，未在 ...